Wichit Arpornwirat

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

Zhongzhen Guan, Binghe Xu, Michelle DeSilvio et al. · Journal of Clinical Oncology · 2013 · 139 citations

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Natasha B. Leighl, Naiyer A. Rizvi, Lopes Gilberto de Lima et al. · Clinical Lung Cancer · 2016 · 39 citations · Full text

Non–small-cell Lung Cancer, Oncology, Medicine +8

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine

Gerald Goh, Ramona Schmid, Kelly Guiver et al. · PLoS Medicine · 2016 · 36 citations · Full text

Phase 2 trial results with the novel neurokinin‐1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

Wichit Arpornwirat, István Albert, Vincent Hansen et al. · Cancer · 2009 · 29 citations